Abstract:
BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research the features and risk factors of ILD in advanced non-small cell lung cancer (NSCLC). METHODS:Between December 2015 and November 2018, 130 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non-irAEs group). Subsequently, we divided the irAEs group into two groups based on the incidence of ILD (ILD group and irAEs-non-ILD group). Treatment efficacy and the characteristics of ILD were evaluated. RESULTS:A total of 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had a higher objective response rate (ORR) compared with irAEs-non-ILD patients and non-irAEs patients (63%, 43% and 22%, respectively). Median progression-free survival (mPFS) was 15.9 months in ILD patients, 5.4 months in irAEs-non-ILD patients and 3.3 months in non-irAEs patients (log-rank test, P = 0.033). Pre-existing interstitial pneumonia (IP) was an independent risk factor for ILD-induced ICIs (odds ratio [OR] 14.7; 95% confidence interval [CI]: 2.16-99.6, P = 0.006). CONCLUSIONS:ORR and PFS were significantly better in ILD patients than in irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor for ILD-induced ICIs.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma Adoi
10.1111/1759-7714.13364subject
Has Abstractpub_date
2020-04-01 00:00:00pages
1052-1060issue
4eissn
1759-7706issn
1759-7714journal_volume
11pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical record...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2011.00107.x
更新日期:2012-05-01 00:00:00
abstract:BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13641
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13308
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13238
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12097
更新日期:2014-07-01 00:00:00
abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12791
更新日期:2018-09-01 00:00:00
abstract:BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12232
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:This study aimed to evaluate the characteristics of active anti-cancer treatment (AAT) compared with best supportive care (BSC) in elderly patients with advanced non-small cell lung cancer (NSCLC). METHODS:A retrospective analysis of 144 patients, aged 70 or older, with stage IIIb/IV NSCLC from 672 patients...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12066
更新日期:2014-03-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract::Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13600
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13163
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12354
更新日期:2016-07-01 00:00:00
abstract:BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12619
更新日期:2018-05-01 00:00:00
abstract::Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13275
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12150
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13644
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13226
更新日期:2019-12-01 00:00:00
abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13127
更新日期:2019-07-01 00:00:00
abstract:BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12847
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13212
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13143
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13522
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13326
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. METH...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12154
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13211
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13526
更新日期:2020-08-01 00:00:00
abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12013
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13080
更新日期:2019-07-01 00:00:00
abstract:BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12627
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy. METHODS:Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12934
更新日期:2019-02-01 00:00:00